Would New SARS-CoV-2 Variants Change the War against COVID-19?

IF 2.2 Epidemiolgia (Basel, Switzerland) Pub Date : 2022-04-29 DOI:10.3390/epidemiologia3020018

Elrashdy M Redwan, Fatma Elrashdy, Alaa A A Aljabali, Wagner Baetas-da-Cruz, Debmalya Barh, Adam M Brufsky, Sk Sarif Hassan, Kenneth Lundstrom, Ángel Serrano-Aroca, Kazuo Takayama, Murtaza M Tambuwala, Bruce D Uhal, Vladimir N Uversky

{"title":"Would New SARS-CoV-2 Variants Change the War against COVID-19?","authors":"Elrashdy M Redwan, Fatma Elrashdy, Alaa A A Aljabali, Wagner Baetas-da-Cruz, Debmalya Barh, Adam M Brufsky, Sk Sarif Hassan, Kenneth Lundstrom, Ángel Serrano-Aroca, Kazuo Takayama, Murtaza M Tambuwala, Bruce D Uhal, Vladimir N Uversky","doi":"10.3390/epidemiologia3020018","DOIUrl":null,"url":null,"abstract":"<p><p>The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike protein the only vaccine target or is a vaccine cocktail better?</p>","PeriodicalId":72944,"journal":{"name":"Epidemiolgia (Basel, Switzerland)","volume":"3 2","pages":"229-237"},"PeriodicalIF":2.2000,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620871/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiolgia (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/epidemiologia3020018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike protein the only vaccine target or is a vaccine cocktail better?

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新的SARS-CoV-2变种会改变对抗COVID-19的战争吗?

科学、私营和工业部门利用各种现有的技术平台，包括疫苗，实现对SARS-CoV-2(严重急性呼吸综合征冠状病毒2)的保护。然而，病毒不断演变成新的高毒力变体，这可能会克服疫苗提供的保护，并可能使人群再次暴露于感染之中。应继续进行大规模疫苗接种，同时采取或多或少的强制性非药物干预措施。因此，需要回答的关键问题是:(一)如何识别SARS-CoV-2的原发性和继发性感染?(二)为什么中和抗体在自然感染和接种疫苗后都不能持久?(iii)哪些因素导致了中和抗体的衰减?(四)可采用何种战略来发展长期群体免疫?(v)刺突蛋白是唯一的疫苗靶点，还是混合疫苗更好?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊